Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zavesca added to CMS drug demo

Executive Summary

Coverage of Actelion/Celltech's oral Gaucher's disease therapy Zavesca (miglustat) has been added to the Medicare Part B drug replacement demonstration project, according to CMS. The demonstration project now provides for interim coverage of approximately 30 oral or self-injected replacements for physician-administered drugs. Enrollment in the project has been described as predictive of enrollment trends in the upcoming Part D benefit (1"The Pink Sheet" July 25, 2005, p. 26)...

You may also be interested in...



Medicare Oral Drug Demonstration A Dud; Will Part D Enrollment Take Off?

Enrollment challenges with the Medicare oral drug replacement demonstration project are highlighting possible stumbling blocks in the Part D implementation process

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel